3 results
Approved WMOCompleted
To determine the influence of darolutamide on the pharmacokinetics of cabazitaxel compared to cabazitaxel alone in mCRPC patients.
Approved WMORecruiting
Primary Objective• To evaluate the efficacy of eptinezumab as add-on to BI for the prevention of migraine and treatment of MOHSecondary Objectives• To evaluate the efficacy of eptinezumab as add-on to BI on health-related quality of life and work…
Approved WMORecruiting
To compare progression free survival (PFS) between treatment with docetaxel or cabazitaxel and darolutamide versus treatment with docetaxel or cabazitaxel in mCRPC patients.